411 MUSCLE PRECURSOR CELLS ARE SAFE FOR THE TREATMENT OF URINARY INCONTINENCE AFTER SURGERY FOR PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Basic Research1 Apr 2011411 MUSCLE PRECURSOR CELLS ARE SAFE FOR THE TREATMENT OF URINARY INCONTINENCE AFTER SURGERY FOR PROSTATE CANCER Meline Stölting, Stefanie Kramer, Stefano Ferrari, Attila Becskei, Tullio Sulser, and Daniel Eberli Meline StöltingMeline Stölting Zürich, Switzerland More articles by this author , Stefanie KramerStefanie Kramer Zürich, Switzerland More articles by this author , Stefano FerrariStefano Ferrari Zürich, Switzerland More articles by this author , Attila BecskeiAttila Becskei Zürich, Switzerland More articles by this author , Tullio SulserTullio Sulser Zürich, Switzerland More articles by this author , and Daniel EberliDaniel Eberli Zürich, Switzerland More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.500AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Skeletal muscle encloses sources of Muscle Precursor Cells (MPCs), which are capable of reconstructing muscle fiber upon injury. MPCs are studied for the treatment of urinary incontinence, also for patients after prostatectomy. However, the safety of injecting these cells in proximity of a potential location of tumor recurrence has not yet been investigated. METHODS We have injected human MPCs, isolated from muscle biopsies harvested from the rectus abdominis, together with different types of prostate cancer, DU145, PC3 and LnCAP (ATCC-LGC Standard) in vivo. Tumor sizes were measured with caliper twice a week for 6 weeks. Lymph node metastasis and tumor phenotypes were analyzed by histology. Tissue physiological activity was assessed by PET scan with F-choline. After harvest tissues were examined by IHC evaluating myogenic differentiation apoptosis and cell cycle arrest of the retrieved tumor. Data was analyzed with SPSS v11 (SPSS Inc, Chicago, IL) by independent samples t-tests or one way ANOVA (p<0.05 is considered significant). RESULTS When co-injected with MPCs, Prostate carcinoma growth was reduced up to 5 fold (fig.1), while lymph node metastases were reduced from 100% after 6 weeks to only 10%. Lymph node and bone metastasis were identified by PET scan with F-choline (Fig.2) on the animals injected with tumor alone. In contrast, no animal bearing tumor co-injected with MPCs presented positive lymph node or metastasis. Histology demonstrates that MPCs differentiated in vivo developing into organized and functional muscle, while the tumor in its proximity were undergoing apoptosis (Caspase3 positive), cell cycle arrest (p21 positive) and expressing the tumor suppressor (BIN1). CONCLUSIONS In this study, we report that the use of MPCs in proximity of prostate cancer is safe in vivo. Further, it decreased tumor growth and metastasis formation could be demonstrated. These results suggest that MPCs can be safely injected on the pelvic floor after prostatectomy. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e166 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Meline Stölting Zürich, Switzerland More articles by this author Stefanie Kramer Zürich, Switzerland More articles by this author Stefano Ferrari Zürich, Switzerland More articles by this author Attila Becskei Zürich, Switzerland More articles by this author Tullio Sulser Zürich, Switzerland More articles by this author Daniel Eberli Zürich, Switzerland More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...